Application of dabigatrane and rivaroxaban in heredicial hematogenous thrombofilia
https://doi.org/10.17238/PmJ1609-1175.2017.3.58-61
Abstract
The experience of using dabigartane and rivaroxaban for secondary prevention of thrombus formation in patients with hereditary hematogenous thrombophilia is considered. Methods. Examined 65 patients with hereditary combined hematogenous thrombophilia aged from 17 to 60. 35 patients took dabigatrane (pradax), 20 patients took rivaroxaban (xarelto), 10 patients took warfarin. Results. After the prescription of dabigatrane or rivaroxaban, no patient recurred any life-threatening thrombotic complications. When dabigatrane was used, hemorrhagic complications were not diagnosed, and only 4 people receiving rivaroxaban had nasal bleeding. Conclusions. Dabigatrane and rivaroxaban are effective and safe drugs for antithrombotic therapy in hereditary hematogenous thrombophilia. Absence of the need for constant laboratory monitoring and extremely rare hemorrhagic complications make it possible to use them in patients living in regions remote from large medical centers.
References
1. Баркаган З.С. Предтромботические состояния и тромбофилии // Руководство по гематологии: в 3 т. Т. 3 / под ред. А.И. Воробьева. М.: Ньюдиамед, 2005. С. 133-147
2. Бокарев И.Н., Попова Л.В., Козлова Т.В. Тромбозы и противотромботическая терапия в клинической практике. М.: МИА, 2009. 511 с
3. Войцеховский В.В. Применение дабигатрана для профилактики тромбообразования у больных гематогенными тромбофилиями // Амурский медицинский журнал. 2014. № 1. С. 92-100
4. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО) // Флебология. 2015. Т. 9, № 4 (вып. 2). 52 с
5. Современные методы распознавания состояния тромботической готовности / под ред. А.П. Момота. Барнаул: Изд-во Алтайского гос. ун-та, 2011. 138 с
6. Bates S.M., Greer I., Pabinger I. [et al.]. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence - Based Clinical Practice Guidelines (8th edition) // Chest. 2008. Vol. 133. P. 844-886.
7. Diener H.C., Connolly S., Ezekowitz M.D. [et al.]. Efficasy and safety of Dabigatran compared with Warfarin Dabigatran in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RELY trial // Lancet Neurol. 2010. Vol. 9 (12). P 1157-1163.
8. Gorst-Rasmussen A., Lip G.Y.H., Larsen T.B. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care // Pharmacoepidemiology and drug safety. 2016. Vol. 25. P. 1236-1244.
9. Granger C.B., Alexander J.H., McMurray J.J. [et al.]. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. 2011. No. 365. Р 981-992.
10. Graham D.J., Reichman M.E., Wernecke M. [et al.]. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with Dabigatran or Rivaroxaban for nonvalvular atrial fibrillation // JAMA Intern. Med. 2016. Vol. 176. P. 1662-1671.
11. McKellar S.H., Abel S., Camp C.L. [et al.]. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves // The Journal of Thoracic and Cardiovascular Surgery. 2011. Vol. 141, No. 6. P. 1410-1416.
12. Patel M.R., Mahaffey K.W., Garg J. [et al.]. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011. No. 365. Р. 883-891.
13. Schiele F., Van Ryn J., Canada K. [et al.]. A specific antidote for dabigatran: functional and structural characterization // Blood. 2012. Vol. 11. P. 1-22.
14. Wann L.S., Curtis A.B., Ellenbogen K.A. [et al.]. 2011 ACCF/ AHA/HRS Focused Update on the management of patients with atrial fibrillation (Update on Dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines // Circulation. 2011. Vol. 123. P. 1144-1150.
15. World Health Organization: Inherited thrombophilia: Report of a Joint WHO. International Society of Thrombosis and Haemostasis (ISTH) Meeting. Geneva: World Health Organization, 1995.
Review
For citations:
Voitsekhovskiy V.V. Application of dabigatrane and rivaroxaban in heredicial hematogenous thrombofilia. Pacific Medical Journal. 2017;(3):58-61. (In Russ.) https://doi.org/10.17238/PmJ1609-1175.2017.3.58-61
Views:
278
Email this article 